{"id":"https://openalex.org/W2321460552","doi":"https://doi.org/10.2174/1871529x11313010002","title":"Novel Targeted Therapies and Combinations for the Treatment of Multiple Myeloma","display_name":"Novel Targeted Therapies and Combinations for the Treatment of Multiple Myeloma","publication_year":2013,"publication_date":"2013-03-01","ids":{"openalex":"https://openalex.org/W2321460552","doi":"https://doi.org/10.2174/1871529x11313010002","mag":"2321460552","pmid":"https://pubmed.ncbi.nlm.nih.gov/22882073"},"language":"en","primary_location":{"id":"doi:10.2174/1871529x11313010002","doi":"https://doi.org/10.2174/1871529x11313010002","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1871529x11313010002","pdf_url":null,"source":{"id":"https://openalex.org/S2764548042","display_name":"Cardiovascular & Haematological Disorders - Drug Targets","issn_l":"1568-0061","issn":["1568-0061","1871-529X","1875-5895","2212-4063"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular & Hematological Disorders-Drug Targets","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103027870","display_name":"Amit Agarwal","orcid":"https://orcid.org/0000-0002-7342-4969","observed_orcids":["https://orcid.org/0000-0002-7342-4969"]},"institutions":[{"id":"https://openalex.org/I4390039223","display_name":"University of Arizona Cancer Center","ror":"https://ror.org/04tvx8690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039223"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amit Agarwal","raw_affiliation_strings":["University of Arizona Cancer Center, Tucson, AZ 86724, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Arizona Cancer Center, Tucson, AZ 86724, USA","institution_ids":["https://openalex.org/I4390039223"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101638085","display_name":"Daruka Mahadevan","orcid":"https://orcid.org/0000-0002-7129-5593","observed_orcids":["https://orcid.org/0000-0002-7129-5593"]},"institutions":[{"id":"https://openalex.org/I138006243","display_name":"University of Arizona","ror":"https://ror.org/03m2x1q45","country_code":"US","type":"education","lineage":["https://openalex.org/I138006243"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daruka Mahadevan","raw_affiliation_strings":["University of Arizona"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Arizona","institution_ids":["https://openalex.org/I138006243"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.8659,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.77660311,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"13","issue":"1","first_page":"2","last_page":"15"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":1.0},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.9319999814033508},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.9539999961853027},{"id":"https://openalex.org/keywords/plasma-cells","display_name":"plasma cells","score":0.7689999938011169},{"id":"https://openalex.org/keywords/bone-marrow-microenvironment","display_name":"bone marrow microenvironment","score":0.9700000286102295},{"id":"https://openalex.org/keywords/drug-mechanisms-of-action","display_name":"drug mechanisms of action","score":0.7279999852180481},{"id":"https://openalex.org/keywords/relapse","display_name":"relapse","score":0.5320000052452087},{"id":"https://openalex.org/keywords/clinical-trials","display_name":"clinical trials","score":0.5789999961853027}],"concepts":[{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.8609529137611389},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6281194090843201},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.5421889424324036},{"id":"https://openalex.org/C2776396001","wikidata":"https://www.wikidata.org/wiki/Q250694","display_name":"Plasma cell","level":3,"score":0.5398805141448975},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.5302070379257202},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5274869799613953},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.507204532623291},{"id":"https://openalex.org/C2776169692","wikidata":"https://www.wikidata.org/wiki/Q4941552","display_name":"Bone disease","level":3,"score":0.4590207040309906},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.43791553378105164},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.4305066764354706},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.4199666380882263},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.4144926071166992},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3882100284099579},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3233248293399811},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.3135620057582855},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2415461540222168},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.19752636551856995},{"id":"https://openalex.org/C2776541429","wikidata":"https://www.wikidata.org/wiki/Q165328","display_name":"Osteoporosis","level":2,"score":0.1110316812992096}],"mesh":[{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D056572","descriptor_name":"Histone Deacetylase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D056572","descriptor_name":"Histone Deacetylase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061988","descriptor_name":"Proteasome Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D061988","descriptor_name":"Proteasome Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2174/1871529x11313010002","doi":"https://doi.org/10.2174/1871529x11313010002","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1871529x11313010002","pdf_url":null,"source":{"id":"https://openalex.org/S2764548042","display_name":"Cardiovascular & Haematological Disorders - Drug Targets","issn_l":"1568-0061","issn":["1568-0061","1871-529X","1875-5895","2212-4063"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular & Hematological Disorders-Drug Targets","raw_type":"journal-article"},{"id":"pmid:22882073","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22882073","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular & hematological disorders drug targets","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320338075","display_name":"Core Research for Evolutional Science and Technology","ror":"https://ror.org/00097mb19"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2010552629","https://openalex.org/W2136640056","https://openalex.org/W1974811251","https://openalex.org/W2072878676","https://openalex.org/W116087060","https://openalex.org/W107503796","https://openalex.org/W2162180804","https://openalex.org/W2001191575","https://openalex.org/W4399322599","https://openalex.org/W1828971193"],"abstract_inverted_index":{"Multiple":[0],"myeloma":[1,49,87,93,131],"is":[2,7],"a":[3,26,53],"B-cell":[4],"neoplasm":[5],"that":[6,102,122,129],"characterized":[8],"by":[9,150],"clonal":[10],"proliferation":[11,104],"of":[12,28,47,60,79,82,97,119,139,163,172,174],"terminally":[13],"differentiated":[14],"plasma":[15,84],"cells.":[16],"Approximately":[17],"20,000":[18],"new":[19],"cases":[20],"are":[21],"diagnosed":[22],"each":[23],"year":[24],"with":[25],"prevalence":[27],"about":[29],"60,000.":[30],"Characteristic":[31],"clinical":[32,181],"features":[33],"include":[34],"bone":[35,99],"disease,":[36,39],"hypercalcemia,":[37],"renal":[38],"anemia":[40],"and":[41,70,75,89,95,105,126,153,177],"infections.":[42],"Advancements":[43],"in":[44,56,159],"our":[45],"understanding":[46,78],"multiple":[48,164],"have":[50,185],"led":[51],"to":[52,180],"significant":[54],"impact":[55],"the":[57,61,66,80,90,98,114,117,124,146,154,169],"natural":[58],"history":[59],"disease.":[62],"Despite":[63],"these":[64,140,151,175,179],"advances":[65],"disease":[67],"remains":[68],"incurable":[69],"most":[71],"patients":[72],"invariably":[73],"relapse":[74],"die.":[76],"Our":[77],"transformation":[81],"normal":[83],"cells":[85,88,94],"into":[86],"interaction":[91],"between":[92],"elements":[96],"marrow":[100],"microenvironment":[101],"sustain":[103],"survival":[106],"has":[107,112],"significantly":[108],"improved.":[109],"This":[110],"knowledge":[111],"paved":[113],"way":[115],"for":[116],"development":[118,160],"novel":[120,141],"drugs":[121,152,176],"target":[123],"genetic":[125],"molecular":[127],"changes":[128],"underlie":[130],"pathophysiology.":[132],"In":[133],"this":[134],"review":[135],"we":[136],"discuss":[137,168],"several":[138],"agents.":[142],"We":[143,166],"focus":[144],"on":[145],"specific":[147],"pathways":[148],"targeted":[149],"role":[155],"they":[156,184],"may":[157],"play":[158],"or":[161],"progression":[162],"myeloma.":[165],"also":[167],"proposed":[170],"mechanism":[171],"action":[173],"correlate":[178],"trials":[182],"where":[183],"been":[186],"investigated.":[187]},"counts_by_year":[{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}